Abstract:Background: Oxaliplatin /5-FU-based regimens have become the standard of care for colon cancer in the adjuvant setting in recent years. As the benefits and outcomes of these regimens in clinical practice is not widely known, the ACCElox registry was set up to assess the therapeutic management of early stage colon cancer with oxaliplatin/5-FU-based regimen and the duration of adjuvant chemotherapy in current clinical practice. Methods: This prospective observational study was conducted between Feb-2006 and Jul-2008 in over 19 countries. Newly diagnosed patients (N = 1,548) with stage II or III colon cancer, who had undergone complete resection of the primary tumor and treated with at least one dose of oxaliplatin were enrolled and followed up till 36 months after the completion of treatment. During the study period, the patient/disease characteristics, dose intensity, toxicity management, treatment delay and duration of disease free survival/relapse were assessed. Results: About 72.7% and 27.3% of the patients were diagnosed with stage III (Dukes C) and stage II (Dukes B2) colon cancer, respectively, with localization in the sigmoid in 33% of the patients.1,152 (74.4%) patients completed the prescribed chemotherapy. Reasons for treatment discontinuation included refusal, adverse events (AEs) or relapse/recurrence of disease in 9.0%, 8.1% and 3.6% of the patients, respectively. Overall, 1,512 (97.6%) patients received at least one cycle of oxaliplatin regimen. The average dose level of oxaliplatin in the first and last treatment cycles were 93.4 mg/m2 and 79.2 mg/m2 respectively. The median actual dose intensity of oxaliplatin per cycle was 149.8mg. Treatment delay occurred in 1,013 patients (67%) and was mainly attributed to AEs (40.9%) and personal inconvenience (35.5%). During the 3-year follow-up period, disease relapse/recurrence occurred in 285 (18.4%) patients and the rate was similar in all the three groups (FOLFOX: 18.1%, FLOX: 19%, and XELOX: 18.6%). The overall number of deaths reported at the end of 3- year study period was 72 (4.7%). The majority of the AEs reported during treatment were of grade 1–2.The most common AEs at any cycle during the treatment period were neutropenia (63.9%), thrombocytopenia (23.3%), diarrhea (9.7%), sensory neuropathy (4.5%) and infection (2.6%). Sensory neuropathy (grade 0-2) was reported in a majority (N = 1471) of the patients at each cycle. Disorders of the central and peripheral nervous system were the most frequent AEs reported at 6 months (54.3% with grade ≥ 1) and 12 months (36.4% with grade ≥ 1) of post-treatment follow up. Conclusion: A majority of the patients completed the prescribed oxaliplatin/5-FU regimen. There was no remarkable difference in the disease-free survival amongst these regimens. No unexpected AEs have been reported. Our results confirm the favorable benefit/risk profile of oxaliplatin/5-FU based regimens in this setting in clinical practice. Also, the improvement in the survival rates with the inclusion of oxaliplatin is in concordance with the findings from the data analysis of five observational data sources reported earlier.1 Reference 1. Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Sturmer T, et al. Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer. J Natl Cancer Inst. 2012;104(3): 211–227.Table Open table in a new tab Table Open table in a new tab

The evidence-based adjuvant chemotherapy for colon cancer

[Gastrointestinal Surgeons Should Master the Adjuvant Therapy of Colorectal Cancer].

Progression in Chemotherapy for Colorectal Cancer

A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience.

Fluorouracil Supplemented with Oxaliplatin or Irinotecan for Solid Tumors: Indications from Clinical Characteristics and Health Outcomes of Patients

[Adjuvant and Perioperative Neoadjuvant Therapy for Colorectal Cancer].

Survival Benefit of Adjuvant Chemotherapy for Patients with Poorly Differentiated Stage IIA Colon Cancer

Adjuvant chemotherapy in ypStage III locally advanced rectal cancer after neoadjuvant treatment with an oxaliplatin-based regimen.

Adjuvant Chemotherapy of Cisplatin, 5-Fluorouracil (5-Fu) Plus Leucovorin (lv) for Esophageal Cancer: A Case-Matched Cohort Study in East China

The studies on adjuvant chemotherapy for Dukes B colorectal cacinoma

Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis

Survival analysis of 65 cases with stage Ⅲ colorectal cancer on adjuvant chemotherapy

The Studies onAdjuvant Chemotherapy for Dukes B Colorectal Carcinoma

Oxaliplatin/5-Fluorouracil(5-Fu)-Based Adjuvant Chemotherapy in Colon Cancer: Results of the Accelox Registry

The Safety and Efficacy of Immune Checkpoint Inhibitor in Combination with FOLFOX As Neoadjuvant/adjuvant Therapy in Patients with Locally Advanced Colon Cancer.

Clinical research of stage Ⅲb and Ⅲc colon cancer treating with Capecitabine as consolidation chemotherapy after adjuvant chemotherapy

FP14.11 Icotinib Versus Chemotherapy As Adjuvant Treatment for Stage II–IIIA EGFR-Mutant NSCLC (EVIDENCE): A Randomized, Open-Label, Phase 3 Study

Oxaliplatin/5-fluorouracil-based Adjuvant Chemotherapy As a Standard of Care for Colon Cancer in Clinical Practice: Outcomes of the ACCElox Registry

Chronomodulated Chemotherapy of Oxaliplatin Combined 5-FU and CF Plus Levamisole on Colorectal Cancer of 41 Cases

[Multicenter Phase II Study of Modified FOLFIRI Regimen in the Advanced Colorectal Cancer Patient Refractory to Fluoropyrimidine and Oxaliplatin].

[Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer]